Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Series B round garners $40mm for Anokion concurrent with Kanyos acquisition

Executive Summary

Anokion SA (autoimmune disease drug development) raised $40mm through its Series B round from investors including Versant Ventures, Novartis Venture Fund, Novo Ventures, Celgene, and undisclosed Swiss private investors. Anokion also announced the acquisition of Kanyos Bio, a firm it spun out in 2015 to develop celiac disease and diabetes candidates. Series B proceeds will support development of Anokion's preclinical pipeline which includes its own ANK780 for multiple sclerosis, and KAN101, which it gains from Kanyos and will continuing developing for celiac disease.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register